Skip to search formSkip to main contentSkip to account menu

doxorubicin liposome

Known as: pegylated liposomal doxorubicin, Liposomal Doxorubicin, doxorubicin liposomal 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2017
Highly Cited
2017
Background:Pembrolizumab (P) is an anti-PD-1 antibody that blocks the interaction between programmed cell death protein 1 (PD-1… 
2017
2017
PHSCN peptide (licensed as ATN-161) is an effective α5β1 integrin inhibitor that has advanced to phase II clinical trials to… 
2017
2017
Lung cancer is the leading cause of cancer-related death worldwide. Most targeted drugs approved for lung cancer treatment are… 
Highly Cited
2016
Highly Cited
2016
BackgroundAcquired drug resistance is the greatest obstacle to the successful treatment of multiple myeloma (MM). Despite recent… 
Highly Cited
2016
Highly Cited
2016
ABSTRACT Hydroxychloroquine (HCQ) inhibits autophagy and therefore can sensitize some cancer cells to chemotherapy, but the high… 
Highly Cited
2015
Highly Cited
2015
BACKGROUND Mesenchymal/metaplastic breast cancers (MpBCs) are often triple-negative (TNBC), and chemo-refractory, and can harbor… 
2013
2013
BACKGROUND Despite improvement with intensive multi-agent chemotherapy, 2-year progression-free survival (PFS) rates for adults… 
2010
2010
BackgroundPlatinum-based combinations are the standard second-line treatment for platinum-sensitive ovarian cancer (OC). This… 
Highly Cited
2006
Highly Cited
2006
5006 Background: Bevacizumab (BV), a recombinant, humanized monoclonal antibody directed against vascular endothelial growth…